Quick Answer
Taysha Gene Therapies, Inc. reported Diluted EPS of $0.34 per share (loss) for fiscal year 2025.
Taysha Gene Therapies, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.34 | +5.6% |
| 2024 | -$0.36 | +62.5% |
| 2023 | -$0.96 | +74.6% |
| 2022 | -$3.78 | +18.5% |
| 2021 | -$4.64 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.09 | +10.0% | +0.0% |
| June 30, 2025 | -$0.09 | +0.0% | -12.5% |
| March 31, 2025 | -$0.08 | +20.0% | +20.0% |
| September 30, 2024 | -$0.10 | +89.2% | -11.1% |
| June 30, 2024 | -$0.09 | +76.3% | +10.0% |
| March 31, 2024 | -$0.10 | +64.3% | +89.2% |
| September 30, 2023 | -$0.93 | -43.1% | -144.7% |
| June 30, 2023 | -$0.38 | +55.3% | -35.7% |
- Taysha Gene Therapies, Inc. showed an increase of +5.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Taysha Gene Therapies, Inc.’s diluted eps has grown by 92.7% (from $4.64 per share (loss) to $0.34 per share (loss)).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: